Skip to content
TrialScanner

NCT03786107

HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib

No phase registeredTerminatedPBYILead

Registry record

Lead sponsor
Puma Biotechnology, Inc.
Conditions
Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer; Metastatic Cervical Cancer
Primary completion
Jan 21, 2021Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03786107 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03786107: HER-Seq: A Blood-based... | TrialScanner